10-Q: Haemonetics Q2 Earnings Rise on Strong Margins, EPS Jumps

Haemonetics Corporation reported increased net income and diluted EPS for Q2 FY26, driven by improved gross profit and operating income despite a revenue decline from planned divestitures and customer transitions.

Summary

• Net revenues decreased by 5.3% to $327.3 million for the three months ended September 27, 2025, and by 4.8% to $648.7 million for the six months, primarily due to the CSL Plasma customer transition and the divestiture of the Whole Blood product line.
• Gross profit increased by 3.9% to $194.7 million for the three months and by 6.8% to $387.0 million for the six months, with gross profit margin improving to 59.5% and 59.7% respectively.
• Operating income rose by 13.1% to $58.5 million for the three months and by 22.9% to $112.4 million for the six months, reflecting pricing benefits, product mix, and decreased restructuring costs.
• Net income increased by 14.3% to $38.7 million for the three months and by 0.7% to $72.7 million for the six months.
• Diluted earnings per share (EPS) grew by 22.7% to $0.81 for the three months and by 7.9% to $1.51 for the six months, benefiting from higher net income and share repurchases.
• The Hospital segment's revenue increased by 5.1% for the three months and 4.7% for the six months, driven by the Hemostasis Management product line.
• Plasma revenue decreased by 9.5% for the three months and 7.0% for the six months, mainly due to lower sales volumes in North America from the CSL Plasma transition.
• Blood Center revenue decreased by 17.6% for the three months and 19.6% for the six months, primarily due to the divestiture of the Whole Blood product line.
• An intangible asset impairment charge of $8.6 million was recorded in Q2 FY26 related to HAS viscoelastic diagnostic devices due to lower revenue projections.
• The company completed a $75.0 million accelerated share repurchase (ASR) in September 2025, repurchasing 1,430,579 shares at an average price of $52.43, with $425.0 million remaining under the 2025 share repurchase program.

Sentiment

Score: 7

Explanation: Despite a revenue decline driven by anticipated strategic shifts, the company demonstrated strong operational efficiency, leading to significant improvements in gross profit, operating income, and diluted EPS. Strategic acquisitions are integrating, and capital is being returned to shareholders through repurchases. The intangible asset impairment and increased interest expense are noted, but overall profitability and strategic execution are positive.

Positives

• Gross profit margins significantly improved to 59.5% (Q2) and 59.7% (YTD), up from 54.2% and 53.2% respectively, indicating enhanced profitability and efficiency.
• Operating income increased by 13.1% for the quarter and 22.9% for the six months, demonstrating strong operational performance.
• Net income per diluted share grew substantially by 22.7% to $0.81 for the quarter and 7.9% to $1.51 for the six months, partly due to share repurchases.
• The Hospital segment showed robust growth, with revenue increasing by 5.1% (Q2) and 4.7% (YTD), driven by strong performance in Hemostasis Management.
• Successful completion of a $75.0 million accelerated share repurchase program, returning capital to shareholders and reducing outstanding shares.
• Pricing benefits across all business units contributed positively to gross profit and operating income.

Negatives

• Net revenues decreased by 5.3% for the three months and 4.8% for the six months, primarily due to the CSL Plasma customer transition and the divestiture of the Whole Blood product line.
• Plasma segment revenue declined by 9.5% (Q2) and 7.0% (YTD) due to lower sales volumes in North America.
• Blood Center segment revenue saw a significant decrease of 17.6% (Q2) and 19.6% (YTD), largely attributable to the Whole Blood product line divestiture.
• An intangible asset impairment charge of $8.6 million was recognized in the second quarter of fiscal 2026 related to the HAS viscoelastic diagnostic devices due to revised revenue projections.
• Interest and other expense, net, increased significantly by $15.9 million for the six months, primarily due to a gain recognized in the prior year on the repurchase of convertible senior notes not recurring.

Risks

• Ability to achieve long-term strategic and financial-improvement goals.
• Demand for and market acceptance risks for new and existing products, including material reductions in purchasing from or loss of a significant customer (e.g., CSL Plasma transition).
• Ability to develop, manufacture, and market new products and technologies successfully and in a timely manner, and the risk of competitors developing superior products.
• Product quality or safety concerns, potentially leading to recalls, regulatory action, reputational damage, declining sales, or litigation.
• Security breaches of products or information technology systems, or those of customers, suppliers, or partners, which could impair business operations or compromise sensitive information.
• Potential that expected strategic benefits from acquisitions (OpSens Inc., Attune Medical) or divestitures (Whole Blood product line) may not be realized or may take longer than expected.
• Pricing pressures from healthcare cost containment trends, including consolidation among healthcare providers.
• Disruptions to the continuity, availability, and pricing of raw materials, finished goods, and components (including from sole-source suppliers), and related manufacturing, sterilization, supply chain, and distribution operations.
• Ability to obtain anticipated benefits of restructuring programs, including the market and regional alignment and portfolio rationalization initiatives.
• Impact of enhanced requirements to obtain regulatory approval in the U.S. and globally, and the associated timing and cost of product approval.
• Ability to comply with U.S. and foreign legal and regulatory requirements, including the U.S. Foreign Corrupt Practices Act, EU Medical Device Regulation, and In Vitro Diagnostic Regulation.
• Impact of changes in U.S. and international tax laws, including the One Big Beautiful Bill Act (OBBBA).
• Ability to meet debt obligations and raise additional capital on acceptable terms.
• Potential impact of convertible senior notes and related capped call transactions.
• Geopolitical and economic conditions in China, Taiwan, Russia, Ukraine, the Middle East, and other foreign jurisdictions.
• Ability to execute and realize anticipated benefits from investments in emerging economies.
• Potential effect of foreign currency fluctuations and interest rate fluctuations on net revenues, expenses, and margins.
• Ability to protect intellectual property and the outcome of patent litigation.
• Costs and risks associated with product liability and other litigation claims.
• Ability to retain and attract key personnel.
• Market conditions impacting stock price and/or share repurchase program, and the possibility of program delays, suspension, or discontinuation.
• Ability to achieve corporate responsibility initiatives and meet evolving stakeholder expectations.
• Impact of actual or threatened public health crises.

Future Outlook

The company's capital allocation strategy prioritizes funding planned internal investments and inorganic opportunities to accelerate long-term growth, alongside offsetting dilution from employee equity grants through share repurchases. The Market and Regional Alignment Initiative is expected to improve operational performance and reduce costs by focusing resources on high-growth markets and geographies, though the exact costs and savings are subject to change.

Management Comments

• Management uses non-GAAP financial measures, in addition to U.S. GAAP, to monitor financial performance, make business decisions, establish budgets, and forecast future results.
• The company's capital allocation strategy continues to prioritize funding of planned internal investments to support the business as well as inorganic opportunities to accelerate its long-term growth plans.
• The new share repurchase program will help to offset the dilutive impact of recent and future employee equity grants.
• The Market and Regional Alignment Initiative is designed to improve operational performance and reduce costs by directing resources toward markets and geographies offering the greatest growth and portfolio advancement opportunities.
• The company believes pursuing intellectual property claims against competitors like Terumo BCT and Fresenius Kabi USA LLC is a necessary and appropriate action to safeguard its innovations, protect its intellectual property, and further the growth and development of its business.

Industry Context

Haemonetics operates in the global medical technology sector, focusing on hospital technologies, plasma collection, and blood center products. The company's strategic acquisitions (Attune Medical, OpSens Inc.) expand its presence in high-growth areas like interventional cardiology and esophageal protection, aligning with broader industry trends towards specialized medical devices and improved patient outcomes. The divestiture of the Whole Blood product line reflects a strategic rationalization to focus on higher-growth segments. The ongoing legal actions to protect intellectual property highlight the competitive nature of the medical device industry and the importance of innovation.

Comparison to Industry Standards

• The company's strategic acquisitions, such as Attune Medical (ensoETM proactive esophageal cooling device) and OpSens Inc. (SavvyWire, OptoWire), position it in growing medical technology niches like electrophysiology and interventional cardiology. These areas are seeing increased investment and innovation across the industry, with competitors like Medtronic, Abbott, and Boston Scientific also active in similar spaces, though specific product-level comparisons are not detailed in the filing.
• The divestiture of the Whole Blood product line to GVS, S.p.A. indicates a strategic focus on higher-growth or more profitable segments, a common practice among diversified medical technology companies seeking to optimize their portfolios. This aligns with industry trends where companies shed non-core assets to concentrate resources.
• The company's improved gross profit margins (59.5% and 59.7%) suggest strong operational efficiency and pricing power, which can be a competitive advantage in the medical device industry, often characterized by intense competition and pricing pressures from healthcare cost containment initiatives.
• The ongoing share repurchase program is a common capital allocation strategy used by mature, profitable companies in the industry to return value to shareholders and manage share dilution from equity compensation, comparable to programs seen at larger medical device firms.

Legal Proceedings

• A complaint filed by Knoninklijke Philips N.V. and IP2IPO Innovations, Ltd. against OpSens and Haemonetics regarding patent infringement was resolved through a confidential settlement agreement in the second quarter of fiscal 2026.
• Haemonetics filed a complaint against Terumo BCT in Q1 FY26 alleging infringement of donor-centric blood plasma collection patents (NexSys PCS with YES and Persona technology). Terumo filed a motion to dismiss, and Haemonetics filed amended complaints adding recently issued patents. Terumo also filed a partial motion to dismiss and inter partes review petitions.
• Haemonetics filed a complaint against Fresenius Kabi USA LLC in Q2 FY26 alleging infringement of donor-centric blood plasma collection patents (NexSys PCS with YES and Persona technology). An amended complaint was filed in October 2025 to add Fenwal Inc. and Fresenius Kabi AG as parties.

Stakeholder Impact

• Shareholders are positively impacted by the increase in diluted EPS and the ongoing share repurchase program, which enhances shareholder value.
• Employees may be affected by the Market and Regional Alignment Initiative, which aims to improve operational performance and reduce costs, potentially involving workforce adjustments.
• Customers in the Hospital segment, particularly those utilizing Hemostasis Management products, are benefiting from volume growth and pricing benefits.
• Customers of the Plasma and Blood Center segments experienced changes due to the CSL Plasma transition and the Whole Blood product line divestiture, which were strategic decisions by the company.
• Creditors are impacted by the company's debt management, including the refinancing of credit facilities and the issuance of convertible notes, with the company reporting compliance with all bank covenants.

Next Steps

• Continue to integrate Attune Medical and OpSens Inc. acquisitions to realize expected synergies and expand market presence.
• Execute the Market and Regional Alignment Initiative to improve operational performance and reduce costs by directing resources toward high-growth markets and geographies.
• Manage the remaining $425.0 million authorization under the 2025 share repurchase program to offset dilution and return capital to shareholders.
• Actively pursue intellectual property claims against Terumo BCT and Fresenius Kabi USA LLC to safeguard innovations and protect business growth.
• Monitor the impact of the One Big Beautiful Bill Act (OBBBA) and other new accounting pronouncements on future financial disclosures and operations.

Key Dates

Recommendation

Haemonetics demonstrated strong operational execution in Q2 FY26, with significant improvements in gross profit, operating income, and diluted EPS, despite expected revenue declines from strategic divestitures and a major customer transition. The company's focus on higher-growth segments like Hospital, coupled with active capital management through share repurchases, is positive. However, the revenue headwinds in Plasma and Blood Center, along with ongoing legal proceedings and an intangible asset impairment, introduce some uncertainty. The stock appears to be in a transitional phase, balancing strategic portfolio adjustments with core profitability improvements. A 'hold' recommendation is appropriate as investors await further clarity on the long-term revenue growth trajectory post-transition and the outcomes of the new strategic initiatives.

Keywords

Medical Technology, Blood Management, Plasma Collection, Hospital Technologies, Interventional Cardiology, Hemostasis Management, Apheresis, Share Repurchase, SEC Filing, Earnings Report, Financial Performance, Acquisitions, Divestitures, Convertible Notes, Healthcare